*2.2. Evaluation of Treatment Response*

The median duration of treatment with Lenvatinib was 11.0 months (interquartile range, IQR 25% 5.2–IQR 75% 26.3). The median follow-up time was 17.0 months (IQR 25% 9.8–IQR 75% 27.0). By the time the follow-up period ended, 11/22 patients were still on Lenvatinib treatment. The mean time from baseline 18F-FDG-PET/CT to treatment initiation was 1.2 months (range 0–4.0), the first follow-up 18F-FDG-PET/CT was performed after a mean of 3.7 months (range 2.0–6.0) and the second follow-up occurred after a mean of 5.6 months (range 3.0–8.0).
